Webcast

Prescient Therapeutics Investor Briefing – 27 May

May 27, 2020

Prescient Therapeutics Investor Briefing – 27 May

Prescient Therapeutics (ASX: PTX) Webcast Replay

Prescient Therapeutics (ASX:PTX) is focused on developing novel, personalised therapies against a range of cancers.

As a part of our ‘Meet the CEOs’ series, CEO Steven Yatomi-Clarke provides valuable insights to the company, its key markets and industry, and future prospects.

Recorded on 27th May 2020 at 12pm (AEST).

Join the next Meet the CEOs webcast

Speak to our Advisor team about this company

FEATURE SPEAKERS

Steven Yatomi-Clarke

CEO & Managing Director

Prescient Therapeutics (ASX:PTX) is focused on developing novel, personalised therapies against a range of cancers. Prescient’s universal CAR-T and targeted therapies are both personalised medicine approaches that seek to improve patient outcomes and provide new tools for clinicians in combating cancer.

Speak to our Advisor team about this company



By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement.